BI 54903/olodaterol fixed-dose combination

Drug Profile

BI 54903/olodaterol fixed-dose combination

Alternative Names: BI-54903/olodaterol

Latest Information Update: 11 Oct 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class Amines; Benzoxazines; Corticosteroids; Ketones
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 10 Oct 2014 No development reported - Phase-I for Asthma (In volunteers) in Germany (Inhalation)
  • 21 Nov 2011 Boehringer Ingelheim withdraws a phase II trial in Asthma prior to enrolment in France and Germany (NCT01428622)
  • 01 Mar 2009 Phase-I clinical trials in Asthma (In volunteers) in Germany (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top